<p>From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices</p>

Abstract

Purpose To quantify rheumatology patient preferences and willingness to pay (WTP) for features differentiating enhanced from standard self-injection devices and to investigate differences among subgroups. Patients and methods Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) were recruited in the UK. A discrete-choice experiment was used to elicit preferences; respondents were presented with 10 choices between 3 different devices: a free standard disposable device, and 2 hypothetical reusable devices characterized by presence/absence of skin sensor, injection speed control, on-screen instructions, injection reminders, electronic log, and large grip. Every hypothetical device included a cost component to assess WTP for each enhanced feature. A random-parameters logit model was used to estimate preference weights and WTP. Results Data were collected from 323 respondents by electronic survey (15/11/2017–15/02/2018; RA: 108; PsA: 103; axSpA: 112). On average, the skin sensor was the most preferred feature (£30), followed by injection speed control, injection reminders, electronic log (~£20 each), on-screen instructions (~£12), and a device with a small, rather than large grip (~£7). Similar preferences for attributes were observed across condition subgroups except for grip size: axSpA patients preferred small grip (~£27); PsA patients preferred large grip (~£19). Overall, respondents preferred reusable devices with all enhanced features (WTP value: £85) over the standard device. RA patients exhibited a higher WTP (£145) than PsA (£102) or axSpA (£62) for the same enhanced device. Conclusion Patients positively valued reusable self-injection devices with enhanced features, which may improve patient experience, potentially improving treatment adherence, clinical, and economic outcomes.

A pilot study examining patient preference and satisfaction for ava®, a reusable electronic injection device to administer certolizumab pegol

“…It should be noted that not all patients preferred the e-Device over their previous self-injection device. This suggests differences in the self-injection device features required and/or preferred by individual patients and supports previous research that found different patients place different values on the features of self-injection devices [25]. For example, previous research has suggested patients who prefer using a PFS over a PFP find it easier to control the self-injection process with a syringe [26].…”

Patient Preference for Self-Injection Devices in Rheumatoid Arthritis: A Discrete Choice Experiment in China

“…The findings of this study are consistent with several previous studies 19 , 26–30 in patients with rheumatic diseases about their preferred attributes in self-injection devices. For instance, Boeri et al found that injection speed control and injection reminders were preferred features for RA patients when selecting self-injection devices.…”

Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis

“…The benefits of quantifying the monetary benefits of health interventions in this way, even in 'free at the point of use' health care systems such as the UK's NHS, have been explored previously (e.g. Boeri et al, 2019;Ikenwilo et al, 2018;Porteous et al, 2016;Scalone et al, 2011).…”